Auris Medical (EARS) Updates on Keyzilen Development; Says TACTT3 Phase 3 Protocol Amended
Tweet Send to a Friend
Auris Medical Holding (Nasdaq: EARS) announced additional clinical data as well as updates to its development plan for Keyzilen (AM-101) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
